State Street
MRTX

State Street’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

State Street’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,324,268
Closed -$137M – 4465
2023
Q4 		$137M Sell
2,324,268
-421,700
-15% -$23.7M 0.01% 1087
2023
Q3 		$120M Buy
2,745,968
+164,229
+6% +$5.86M 0.01% 1067
2023
Q2 		$93.3M Buy
2,581,739
+271,919
+12% +$11.2M ﹤0.01% 1265
2023
Q1 		$85.9M Sell
2,309,820
-235,756
-9% -$10.6M ﹤0.01% 1287
2022
Q4 		$115M Buy
2,545,576
+974,037
+62% +$63M 0.01% 1077
2022
Q3 		$110M Sell
1,571,539
-305,076
-16% -$22.6M 0.01% 1056
2022
Q2 		$126M Buy
1,876,615
+453,050
+32% +$28.8M 0.01% 1010
2022
Q1 		$117M Buy
1,423,565
+388,101
+37% +$39.7M 0.01% 1181
2021
Q4 		$152M Buy
1,035,464
+119,851
+13% +$18.6M 0.01% 1011
2021
Q3 		$162M Buy
915,613
+75,935
+9% +$12.2M 0.01% 959
2021
Q2 		$136M Sell
839,678
-218,493
-21% -$35.1M 0.01% 1069
2021
Q1 		$181M Sell
1,058,171
-17,862
-2% -$3.54M 0.01% 837
2020
Q4 		$236M Sell
1,076,033
-11,807
-1% -$2.55M 0.01% 694
2020
Q3 		$181M Sell
1,087,840
-148,358
-12% -$20.3M 0.01% 717
2020
Q2 		$141M Sell
1,236,198
-35,598
-3% -$3.45M 0.01% 788
2020
Q1 		$97.8M Buy
1,271,796
+37,034
+3% +$3.32M 0.01% 872
2019
Q4 		$159M Sell
1,234,762
-88,508
-7% -$8.54M 0.01% 791
2019
Q3 		$103M Buy
1,323,270
+181,147
+16% +$17M 0.01% 985
2019
Q2 		$118M Sell
1,142,123
-269,916
-19% -$21M 0.01% 927
2019
Q1 		$104M Sell
1,412,039
-119,510
-8% -$8.13M 0.01% 987
2018
Q4 		$65M Buy
1,531,549
+128,033
+9% +$5.1M 0.01% 1187
2018
Q3 		$66.1M Buy
1,403,516
+427,694
+44% +$23.8M 0.01% 1346
2018
Q2 		$48.1M Buy
975,822
+278,115
+40% +$10.5M ﹤0.01% 1517
2018
Q1 		$21.4M Sell
697,707
-16,574
-2% -$460K ﹤0.01% 2000
2017
Q4 		$13M Buy
714,281
+683,864
+2,248% +$10.6M ﹤0.01% 2326
2017
Q3 		$356K Buy
30,417
+16,900
+125% +$97.8K ﹤0.01% 3527
2017
Q2 		$49K Sell
13,517
-199,021
-94% -$762K ﹤0.01% 3595
2017
Q1 		$1.11M Buy
212,538
+22,359
+12% +$123K ﹤0.01% 3235
2016
Q4 		$905K Buy
190,179
+20,945
+12% +$114K ﹤0.01% 3301
2016
Q3 		$1.12M Buy
169,234
+1,157
+0.7% +$6.16K ﹤0.01% 3160
2016
Q2 		$917K Sell
168,077
-182,448
-52% -$2.91M ﹤0.01% 3294
2016
Q1 		$7.5M Sell
350,525
-19,071
-5% -$426K ﹤0.01% 2332
2015
Q4 		$11.7M Buy
369,596
+226,957
+159% +$8.02M ﹤0.01% 2090
2015
Q3 		$4.91M Buy
142,639
+24,826
+21% +$750K ﹤0.01% 2533
2015
Q2 		$3.71M Buy
117,813
+28,017
+31% +$826K ﹤0.01% 2791
2015
Q1 		$2.63M Buy
89,796
+22,726
+34% +$533K ﹤0.01% 2914
2014
Q4 		$1.24M Buy
67,070
+3,090
+5% +$52.1K ﹤0.01% 3215
2014
Q3 		$1.12M Buy
63,980
+6,237
+11% +$116K ﹤0.01% 3221
2014
Q2 		$1.16M Buy
+57,743
New +$1.11M ﹤0.01% 3220

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

State Street's MRTX Position: Q1 2024 in Review

State Street sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 2,324,268 shares — an estimated $137M sold.

State Street first reported a position in MRTX in Q2 2014 and held it in 39 quarters. The position peaked at $236M in Q4 2020. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • State Street reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • State Street sold 2,324,268 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $137M.
  • State Street first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2014 and held it in 39 quarters.
  • State Street's Mirati Therapeutics, Inc. Common Stock position peaked at $236M in Q4 2020.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on State Street's 13F filing for Q1 2024, filed 15 May 2024.